The Latest Developments In HIV Vaccines
DOI:
https://doi.org/10.59188/eduvest.v4i9.6369Keywords:
HIV, Vaccine, History of HIV Vaccines, HIV Vaccine DevelopmentAbstract
Medical knowledge of HIV and AIDS is rapidly evolving, leading to increased understanding of the disease, its immunology, and clinical manifestations. Antiretroviral therapy has provided a means of controlling but not curing the disease. However, new challenges are emerging. A vaccine is one prevention tool that remains elusive. Research over the past 40 years illustrates how difficult it is to induce effective immunity against this virus. Progress of vaccine development has been hindered by the extensive genetic variability of HIV, our limited understanding of immune responses required to protect against HIV acquisition, and funding issues. Since the beginning of HIV vaccine development, it is worth noting that there have been many advances and innovations to make HIV vaccine more effective and safer.
References
Arunachalam, P. S., Charles, T. P., Joag, V., Bollimpelli, V. S., Scott, M. K. D., Wimmers, F., Burton, S. L., Labranche, C. C., Petitdemange, C., & Gangadhara, S. (2020). T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nature Medicine, 26(6), 932–940.
Bennett, J. E., & Blaser, M. J. (2015). Mandell, Douglas, and Bennett’s principles and practice of infectious diseases.
Bertels, F., Marzel, A., Leventhal, G., Mitov, V., Fellay, J., Günthard, H. F., Böni, J., Yerly, S., Klimkait, T., & Aubert, V. (2018). Dissecting HIV virulence: heritability of setpoint viral load, CD4+ T-cell decline, and per-parasite pathogenicity. Molecular Biology and Evolution, 35(1), 27–37.
Development, H. V. (2022). NIH: National Institute of Allergy and Infectious Diseases. Accessed August 5, 2022. https://www.niaid.nih.gov/diseases-conditions/hiv-vaccine-development.
Fidler, S., Stöhr, W., Pace, M., Dorrell, L., Lever, A., Pett, S., Kinloch-de Loes, S., Fox, J., Clarke, A., & Nelson, M. (2020). Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. The Lancet, 395(10227), 888–898.
Fortner, A., & Bucur, O. (2022). mRNA-based vaccine technology for HIV. Discoveries, 10(2).
Hokello, J., Sharma, A. L., & Tyagi, M. (2021). An update on the HIV DNA vaccine strategy. Vaccines, 9(6), 605.
Indonesia., K. K. R. (2016). Kajian Epidemiologi HIV Indonesia 2016. Published online 2017.
Jones, L. D., Moody, M. A., & Thompson, A. B. (2020). Innovations in HIV-1 vaccine design. Clinical Therapeutics, 42(3), 499–514.
Khalid, K., Padda, J., Khedr, A., Ismail, D., Zubair, U., Al-Ewaidat, O. A., Padda, S., Cooper, A. C., & Jean-Charles, G. (2021). HIV and messenger RNA (mRNA) vaccine. Cureus, 13(7).
Kim, J., Vasan, S., Kim, J. H., & Ake, J. A. (2021). Current approaches to HIV vaccine development: a narrative review. Journal of the International AIDS Society, 24, e25793.
Larijani, M. S., Ramezani, A., & Sadat, S. M. (2019). Updated studies on the development of HIV therapeutic vaccine. Current HIV Research, 17(2), 75–84.
Lee, J., Kumar, S. A., Jhan, Y. Y., & Bishop, C. J. (2018). Engineering DNA vaccines against infectious diseases. Acta Biomaterialia, 80, 31–47.
Liu, Y., Cao, W., Sun, M., & Li, T. (2020). Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. Emerging Microbes & Infections, 9(1), 194–206.
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2019). Peptide-based vaccines: current progress and future challenges. Chemical Reviews, 120(6), 3210–3229.
Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019). mRNA as a transformative technology for vaccine development to control infectious diseases. Molecular Therapy, 27(4), 757–772.
Mdluli, T., Jian, N., Slike, B., Paquin-Proulx, D., Donofrio, G., Alrubayyi, A., Gift, S., Grande, R., Bryson, M., & Lee, A. (2020). RV144 HIV-1 vaccination impacts post-infection antibody responses. PLoS Pathogens, 16(12), e1009101.
Merati, T. P., Karyana, M., Tjitra, E., Kosasih, H., Aman, A. T., Alisjahbana, B., Lokida, D., Arlinda, D., Maldarelli, F., & Neal, A. (2021). Prevalence of HIV infection and resistance mutations in patients hospitalized for febrile illness in Indonesia. The American Journal of Tropical Medicine and Hygiene, 105(4), 960.
Ng’uni, T., Chasara, C., & Ndhlovu, Z. M. (2020). Major scientific hurdles in HIV vaccine development: historical perspective and future directions. Frontiers in Immunology, 11, 590780.
Pardi, N., LaBranche, C. C., Ferrari, G., Cain, D. W., Tombácz, I., Parks, R. J., Muramatsu, H., Mui, B. L., Tam, Y. K., & Karikó, K. (2019). Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques. Molecular Therapy-Nucleic Acids, 15, 36–47.
Pitisuttithum, P., & Marovich, M. A. (2020). Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges. Expert Review of Vaccines, 19(2), 133–142.
Roark, R. S., Li, H., Williams, W. B., Chug, H., Mason, R. D., Gorman, J., Wang, S., Lee, F.-H., Rando, J., & Bonsignori, M. (2021). Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science, 371(6525), eabd2638.
Shapiro, S. Z. (2020). HIV vaccine development: 35 years of experimenting in the funding of biomedical research. Viruses, 12(12), 1469.
Tatoud, R., Snow, W., & Esparza, J. (2021). A transformed global enterprise for an HIV vaccine. African Journal of Reproduction and Gynaecological Endoscopy, 24(S7), e25822.
WHO. (2023a). HIV. HIV/AIDS in the South-East Asia. Accessed October 4, 2023. https://www.who.int/southeastasia/health-topics/hiv-aids.
WHO. (2023b). HIV. The Global Health Observatory. Accessed October 4, 2023. https://www.who.int/data/gho/data/themes/hiv-aids.
Xu, S., Yang, K., Li, R., & Zhang, L. (2020). mRNA vaccine era—mechanisms, drug platform and clinical prospection. International Journal of Molecular Sciences, 21(18), 6582.
Published
Issue
Section
License
Copyright (c) 2024 I Ketut Agus Somia, Gerry Setiawan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
